Arrowhead to Participate in Panel Discussions at 16th Annual BIO CEO &
BIO CEO & Investor Conference 2014
PASADENA, Calif. -- February 4, 2014
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company
developing targeted RNAi therapeutics, today announced that members of
management will be panelists on two panel discussions at the 16^th Annual BIO
CEO & Investor Conference on Monday, February 10, 2014. President and CEO,
Christopher Anzalone, Ph.D., and COO and head of R&D, Bruce Given, M.D., will
participate in discussions at 9:00 am EST titled, “Solution Development:
Aiming the Whole Pipeline at a Single Goal,” and at 10:30am EST titled,
“Delivering the [RNAi] Goods,” respectively.
Now in its sixteenth year, the BIO CEO & Investor Conference is the largest
investor conference focused on established and emerging publicly traded and
select private biotech companies. The conference is being held February 10-11
at the Waldorf Astoria in New York City.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and partner-based programs in obesity and oncology.
For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to firstname.lastname@example.org.
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Press spacebar to pause and continue. Press esc to stop.